IOVA Iovance Biotherapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IOVA

Price (delayed)

$9.87

Market cap

$4.47B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.7

Enterprise value

$4.4B

?
Relative Growth: Rel. Growth: 59
Relative Strength: Rel. Strength: 99
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 25

Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to ...

Highlights
The gross profit has soared by 95% YoY and by 40% from the previous quarter
The company's gross margin rose by 45% YoY and by 23% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.iovance.com

Key stats

What are the main financial stats of IOVA

IOVA stock price

How has the Iovance Biotherapeutics stock price performed over time
Intraday
5.45%
1 week
17.08%
1 month
41.4%
1 year
329.13%
YTD
261.54%
QTD
137.26%

Financial performance

How have Iovance Biotherapeutics's revenue and profit performed over time
Revenue
$324.97M
Gross profit
$157.29M
Operating income
-$301.31M
Net income
-$289.52M
Gross margin
48.4%
Net margin
-89.1%
The gross profit has soared by 95% YoY and by 40% from the previous quarter
The operating margin is up by 45% YoY and by 27% from the previous quarter
The company's gross margin rose by 45% YoY and by 23% QoQ
Iovance Biotherapeutics's net margin has increased by 45% YoY and by 28% from the previous quarter

Price vs fundamentals

How does IOVA's price correlate with its fundamentals

Growth

What is Iovance Biotherapeutics's growth rate over time

Valuation

What is Iovance Biotherapeutics stock price valuation
P/E
N/A
P/B
5.99
P/S
13.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.54
The EPS has grown by 43% YoY and by 24% from the previous quarter
IOVA's price to book (P/B) is 100% more than its 5-year quarterly average of 3.0
IOVA's equity is up by 5% year-on-year
IOVA's revenue is up by 35% YoY and by 14% QoQ

Efficiency

How efficient is Iovance Biotherapeutics business performance
The ROS has grown by 44% YoY and by 27% from the previous quarter
The return on assets has increased by 23% year-on-year and by 19% since the previous quarter
The ROE is up by 23% year-on-year and by 19% since the previous quarter
Iovance Biotherapeutics's ROIC has increased by 21% from the previous quarter and by 18% YoY

Dividends

What is IOVA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IOVA.

Financial health

How did Iovance Biotherapeutics financials performed over time
The company's quick ratio rose by 34% YoY and by 23% QoQ
The current ratio has increased by 33% YoY and by 21% from the previous quarter
Iovance Biotherapeutics's debt is 94% less than its equity
IOVA's debt to equity is down by 25% YoY and by 14% from the previous quarter
Iovance Biotherapeutics's debt has decreased by 13% YoY and by 3.7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.